Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
165.39%
-
Total 13F principal
-
$519,084,931
-
Principal change
-
+$509,280,931
-
Total reported market value
-
$858,521,718
-
Number of holders
-
35
-
Value change
-
+$842,352,735
-
Number of buys
-
34
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q1 2021
As of 31 Mar 2021,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
35 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$519,084,931
in principal (par value) of the bond.
The largest 10 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), WOLVERINE ASSET MANAGEMENT LLC, Polar Asset Management Partners Inc., HIGHBRIDGE CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, DEUTSCHE BANK AG\, Aequim Alternative Investments LP, CITIGROUP INC, WESTWOOD HOLDINGS GROUP INC., and Magnetar Financial LLC.
This page lists
36
institutional bondholders reporting positions
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.